Start with a phone call. Your doctor’s office has a triage line and a nurse will talk it through with you. They are genuinely good at this, they do it all day, and it costs nothing. Most practices have a phone line where a nurse takes calls about whether something needs to be seen, and how soon. It is often not advertised — you ring the main number and ask to speak to the triage nurse. There is no charge and you do not need an appointment to use it.
If it feels more serious than that, go to urgent care. You will usually be seen faster than at a hospital, and the care is good.
If it feels life-threatening, call 911 or go to the emergency room. Do not wait until you are sure.
Which one is yours to decide, not ours. But our advice is to assume it is worse than it looks and take the more cautious road. And trust your body — if it is telling you something is wrong, it is probably right. The best possible outcome of a trip to the emergency room is walking out saying well, that was a waste of an evening — but I feel a lot better knowing it is nothing serious.
Before you call, have these ready. They are what the nurse will ask, and the call goes better when you are not working them out on the phone.
You are not diagnosing yourself by having this ready. You are handing them the things they would otherwise spend the call extracting — and the decision stays entirely theirs.
Writing to the portal instead of calling? The same list works, in that order, in one message. Put the direction it is going and the immune-system line near the top — portal messages get read quickly, and those two change how the rest is read.
The short answer, before anything else.
Most “sinus headaches” are migraine. It is the most common misnaming in primary care, and there is a test on this page that separates them.
→ where this is explained: “Is it really my sinuses?” Here is the test
The name matters because the treatments are different. Years can go by treating the wrong thing, and the newer migraine treatments are a genuine breakthrough that you are not offered under the wrong label.
→ where this is explained: Why the newest treatments are a real breakthrough
There is a trap nobody warns you about. Painkillers taken often enough begin to cause the headaches they are treating. It looks exactly like the condition getting worse.
→ where this is explained: The trap no one warns you about: rebound headaches
The one thing to do next: Worth asking: “Could what I have been calling sinus or tension headaches actually be migraine?” and “Am I a candidate for the newer CGRP treatments — a shot or a gepant — and which would fit me?”
Everything below explains each of those, in whatever order suits you.
None of those? Then nothing below is an emergency, and you can read the rest calmly. That list is longer than most on this site because headache is one of the places where the rare dangerous thing looks, at first, exactly like the common harmless one.
A word about the word. Migraine is the precise term, and this page uses it even though you may have arrived calling it something else.
If you would have said sinus headache, tension headache, my head thing — that is not a mistake on your part, it is the most common misnaming in all of primary care, and it is the subject of this page rather than a quibble about it. The research is filed under migraine. That is the word that works in a search, on a form, and in front of a doctor.
The single most common mistake in the whole of headache medicine.
Nine out of ten people certain they had sinus headaches turned out to have migraine.
When researchers studied people certain they had sinus headaches, about 9 out of 10 actually had migraine. Many had been given antibiotics or even sinus surgery that never fixed the real problem.
Migraine fools people because it can cause a stuffy or runny nose and pressure across the face. A few clues point away from sinuses and toward migraine: the pain throbs, light and sound make it worse, you feel queasy, and an attack usually lasts hours to a day or two rather than dragging on for many days.
And here is a practical tell — if a migraine rescue drug like a triptan relieves what you have been calling a “sinus headache”, it was almost certainly migraine. Recurring “sinus headaches” that keep coming back despite antibiotics are a red flag for missed migraine.
Worth asking: “Could what I have been calling sinus or tension headaches actually be migraine?”
Grade B — In a primary-care study of nearly 3,000 people with self- or provider-labelled sinus headache, about 90% actually met criteria for migraine.
Grade B — In a separate cohort, 81.5% of migraine patients had been labelled with sinusitis, carrying a mean diagnostic delay of 7.75 years and ranging as high as 38 years.
Grade B — The American Migraine Study II found that only about half of people eventually diagnosed with migraine knew they had it beforehand, with sinus headache the most common mislabel.
Grade B — The cost is not trivial: misdiagnosed patients are more likely to develop chronic migraine and medication-overuse headache, and most receive antibiotics or sinus surgery that do not relieve the underlying disease.
Not random pain. A chain reaction.
Once you see the chain, every symptom and every treatment makes sense.
It often starts with a wave. In migraine with “aura” — the flashing lights, blind spots, or shimmering zigzag lines that about one in three migraineurs get — a slow wave of electrical activity creeps across the surface of the brain, trailed by a wave of quiet. It moves slowly, which is why an aura drifts and spreads over several minutes instead of switching on all at once. People who never see an aura are thought to have a related kind of brain over-excitability.
The wave irritates a major nerve. As it passes, it stirs up the trigeminal nerve — the large nerve that carries feeling from your face and from the lining around your brain.
The nerve releases a pain molecule called CGRP. When the trigeminal nerve fires, it dumps out a molecule named CGRP. CGRP swells and inflames the blood vessels in the lining around the brain, and that inflammation is the throbbing pain. The same nerve traffic drives the nausea and the misery of light and sound.
How do we know this is the real chain? Because CGRP rises in the blood during an attack and drops back to normal when the pain lifts. That single fact is the reason behind the biggest treatment advance in decades.
Worth asking: “What is actually happening in my head when I get one?”
For most of history there were no migraine drugs — only drugs borrowed from other diseases.
The CGRP medicines are the first treatments designed to block the actual migraine molecule.
Doctors prevented migraine with blood-pressure pills, epilepsy pills, and antidepressants. They do help some people, but none were built for migraine, and their side effects make many people quit.
There are two kinds of CGRP medicine, and it is worth knowing both names so you can ask for them. The shots, called CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab), are taken monthly or every three months to prevent attacks. The pills and nasal sprays, called gepants (ubrogepant, rimegepant, atogepant, zavegepant), can stop an attack in progress, and some also prevent them.
Here is the part that matters most. In 2024 headache experts said these can now be a first choice. You no longer have to fail the older borrowed drugs first. If no one has ever offered you a CGRP treatment, that is a specific, named thing to ask about at your next visit.
A few other real options round out the picture: lasmiditan, a newer pill for people who cannot take triptans, often because of heart concerns; triptans themselves, still a strong rescue medicine for many; small wearable devices that calm the nerve signal with no drug at all; and Botox injections, well proven for people with frequent, near-daily migraine.
Worth asking: “Am I a candidate for the newer CGRP treatments — a shot or a gepant — and which would fit me?”
Grade A — In 2024 the American Headache Society endorsed CGRP-targeting therapies, both monoclonal antibodies and gepants, as first-line prevention, removing the old requirement to fail repurposed drugs first.
The rescue becomes the disease.
The medicines you take to stop an attack can, past a certain point, start causing attacks.
Doctors call it medication-overuse headache, or rebound. It happens quietly: you take more painkillers because the headaches come more often, and the headaches come more often partly because you are taking more painkillers.
The danger lines are specific. You are at risk if, for more than three months, you take triptans, opioids, or combination painkillers such as Excedrin on 10 or more days a month — or plain painkillers like paracetamol, ibuprofen, aspirin or naproxen on 15 or more days a month.
This is not slow or rare. On average, overusing triptans can turn occasional migraine into near-daily chronic migraine in under two years.
A simple rule of thumb protects most people: try not to use acute headache medicine on more than two days in any week.
If you are already past these limits, do not stop everything suddenly — some medicines need a careful plan with your doctor — but raise it soon, because breaking this cycle is often the very thing that turns chronic migraine back into something manageable.
Worth asking: “How many days a month am I using rescue medicine, and could that be causing rebound headaches?”
Neither dismissed nor oversold.
Genuinely promising, not yet proven, and not a replacement for real treatment.
People with migraine do tend to carry a different mix of gut bacteria than people without it. The link is real enough that in one study of children, a single chemical made by gut bacteria predicted who had migraine with about 87% accuracy.
Probiotics are a mixed bag. In people with chronic, near-daily migraine, a high-dose multi-strain probiotic cut attacks sharply in one trial — but in people with occasional migraine, probiotics did no better than a dummy pill.
What is safe and sensible right now, while the science matures: eat enough fibre, do not skip meals, and protect your sleep. These steady the gut and the brain at the same time, cost nothing, and carry no downside.
Grade C — A paediatric study found migraine children had a skewed gut-controlled tryptophan pathway, with a kynurenic-to-quinolinic acid ratio yielding diagnostic accuracy of AUC 0.871.
Grade C — The probiotic data is a textbook case of why averaging misleads. The peak: a 14-strain probiotic cut chronic-migraine attack frequency by about 9.7 days a month against 0.2 for placebo. The valley: a 7-strain trial showed no benefit in episodic migraine, and a meta-analysis of three trials found no significant effect.
Grade C — Genetic (Mendelian randomisation) studies offer the strongest causal signal so far, implicating dysbiosis of Bifidobacteriaceae, but rely on mostly-European genome data and remain directional rather than definitive.
Grade U — Short-chain fatty acids reduced pain behaviour in a mouse model. No human trial exists.
Grade U — Faecal microbiota transplantation for migraine is an empty cell. No published trials exist at all.
Those last two are on this page precisely because they are empty. An absence that is stated is a finding; an absence that is quietly omitted looks like an answer.
Cheap, decent evidence, and they work by the same route.
They support the brain’s energy supply, which tends to run low in migraine.
Magnesium has the strongest evidence, at a typical 400 to 600 mg a day. Riboflavin (vitamin B2) at 400 mg a day, and CoQ10 at 100 mg three times daily (or 300 mg once), also help some people and have very few side effects.
All three can take up to three months to show benefit, so do not give up at three weeks.
One warning worth repeating: butterbur used to be recommended, and is no longer advised, because some forms can damage the liver. “Natural” is not the same as “safe”. Tell your doctor about anything you take, since some supplements interact with medicines.
Worth asking: “Would magnesium, riboflavin, or CoQ10 be reasonable for me to try?”
Grade B — Magnesium carries a Level B recommendation; riboflavin and CoQ10 sit at Level C with clean safety profiles; feverfew is second-line Level B with safety caveats.
Grade B — Butterbur once held strong evidence and is no longer recommended, because of liver-toxicity risk in unpurified preparations. That is a grade that had to be revised downward, and it is worth seeing one, because it is what an honest grade looks like when the evidence turns.
Desperation is exactly what untested cures are sold to.
The instinct to try anything is not foolish. It is the receipt for a system that moved too fast.
When a disease causes this much suffering and is missed this often, feeling desperate enough to try anything is completely understandable. About half of people with migraine turn to alternative remedies, and most do so because regular care failed them or caused side effects.
One filter protects you. Be very wary of anything that promises a complete cure, anything that costs a great deal out of your own pocket, or anything that tells you to stop your real treatment. Put your money toward the proven options above and toward time with a real headache specialist — not toward whatever is marketed hardest.
One of the most powerful things you can do, and it costs nothing.
The number that catches the rebound trap before it catches you.
For a few weeks, note the day each attack hits, how bad it is, how you slept, what you ate, where you are in your cycle if that applies — and, most important, how many days you used acute medicine.
That last number is the one that catches the rebound trap before it catches you, and it turns a rushed seven-minute appointment into a conversation backed by real data. A free phone app or a small notebook both work.
Pointed questions lead to better care, especially when time in the room is short.
Bring these to your next visit.
The second-ranked disability disease, funded as if it barely exists.
In 2017, US research funding for migraine came to about fifty cents per affected person per year.
Migraine affects roughly 1.2 billion people worldwide, about 15% of everyone alive, and ranks as the second leading cause of years lived with disability of any disease — first among children, adolescents and adults under 50.
To merely match the average disease-funding-to-burden ratio, migraine would need roughly ten times more funding — on the order of 200 million dollars a year.
Some of why: it rarely kills, and funding tracks mortality more than suffering. It is female-predominant, and female-dominant conditions are systematically underfunded relative to burden. And industry has funded the late-stage drugs but not the early, mechanistic, cross-system science — which is exactly where the gut question lives.
Grade A — ~1.2 billion people, ~15% of the global population, second leading cause of years lived with disability; first among under-50s. In the United States about 12%, near 39 million, peaking between 30 and 49 — the most productive working years.
Grade A — Global prevalence grew 58% between 1990 and 2021. Adolescents show the fastest growth, and male prevalence is climbing four to five times faster than female.
Grade A — Tension-type headache is more common, but migraine causes roughly 90% of all headache-related disability. Prevalence and burden are different axes, and migraine sits at the top of the burden axis.
Grade B — 2017 US National Institutes of Health funding for migraine research came to about fifty cents per affected person per year.
Migraine is a real, common, disabling brain disease driven by a specific nerve and a specific molecule — not a personal failing, and not just a bad headache.
It is often misnamed, which steals years from people before the right treatment reaches them. Today there are more effective treatments than ever, several of them brand new and built for this disease alone.
You deserve an accurate diagnosis and a real plan, and everything here is meant to help you ask for both with confidence.
Written in June 2026. Published here in September.
This page is the plain-language migraine guide from the Vermont Synergy Initiative, version 1.2a, written for one person who needed it and never put anywhere a stranger could find it. Its companion technical document carries the per-claim grades, and those grades have been brought across onto this page rather than left behind in a file nobody reads.
The grade travels with the claim. Where the evidence is strong it says A; where it is suggestive it says C; and where there is no human evidence at all it says U and names the gap.
Nothing on this page is a diagnosis, and none of it replaces someone who can examine you. What it is for is walking into that appointment able to name what you have, ask for treatments by name, and check whether the medicine meant to rescue you has quietly become part of the problem.